Jun Tie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jun Tie has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
Xulong Yuan
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi'an, China
10 shared publicationsJiao Xu
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi'an, China
8 shared publicationsJing Niu
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi'an, China
7 shared publicationsXiaoyuan Gou
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi’an, China
7 shared publicationsYing Zhu
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi’an, China
6 shared publicationsChuangye He
National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi’an, China
5 shared publications
Latest Publications
- 26 August 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (11)
Transjugular Mesenteric–Caval Shunt for Cavernous Transformation of the Portal Vein Secondary to Myelofibrosis
- 26 August 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (11)
Transjugular Mesenteric–Caval Shunt for Cavernous Transformation of the Portal Vein Secondary to Myelofibrosis
- Open Access
Comparison of underdilated versus standard transjugular intrahepatic portosystemic shunt in preventing rebleeding from oesophagogastric varices in patients with cirrhosis in Chinese tertiary hospitals: protocol for a multicentre randomised controlled trial (UVR-TIPS trial)
Introduction: Hepatic encephalopathy (HE) is a major complication following transjugular intrahepatic portosystemic shunt (TIPS) placement, significantly affecting patients’ quality of life and long-term prognosis. This study aims to compare the efficacy of underdilated TIPS versus standard TIPS in preventing variceal rebleeding in patients with cirrhosis and portal hypertension and to evaluate the incidence of post-procedural HE. Methods and analysis: This multicentre randomised controlled trial will be conducted across five Grade A tertiary hospitals in China. A total of 648 patients with portal hypertension-related oesophagogastric variceal bleeding undergoing TIPS will be enrolled and randomly assigned in a 1:1 ratio to either the experimental or control group. In the experimental group, underdilated TIPS will be performed using 6 mm balloon for stent expansion. In the control group, standard TIPS will be performed using progressive balloon dilation, starting at 8 mm and increasing stepwise as needed until the portosystemic pressure gradient is reduced to <12 mm Hg. The primary endpoint is the rebleeding rate over the entire follow-up period after TIPS. Secondary endpoints include the incidence of HE and liver function impairment. All statistical analyses will be performed using SPSS V.27.0 (IBM, Armonk, New York, USA), with a significance level set at p<0.05. Ethics and dissemination: The study protocol (V.2, 1 July 2025) has been approved by the Medical Ethics Committee of the First Affiliated Hospital of Air Force Medical University (Approval No.: KY20252233-F-2). Written informed consent will be obtained from all participants prior to enrolment. Findings will be presented at academic conferences and published in peer-reviewed journals. Trial registration number: ChiCTR2500110490; NCT07253389 .
Open AccessComparison of underdilated versus standard transjugular intrahepatic portosystemic shunt in preventing rebleeding from oesophagogastric varices in patients with cirrhosis in Chinese tertiary hospitals: protocol for a multicentre randomised controlled trial (UVR-TIPS trial)
Introduction: Hepatic encephalopathy (HE) is a major complication following transjugular intrahepatic portosystemic shunt (TIPS) placement, significantly affecting patients’ quality of life and long-term prognosis. This study aims to compare the efficacy of underdilated TIPS versus standard TIPS in preventing variceal rebleeding in patients with cirrhosis and portal hypertension and to evaluate the incidence of post-procedural HE. Methods and analysis: This multicentre randomised controlled trial will be conducted across five Grade A tertiary hospitals in China. A total of 648 patients with portal hypertension-related oesophagogastric variceal bleeding undergoing TIPS will be enrolled and randomly assigned in a 1:1 ratio to either the experimental or control group. In the experimental group, underdilated TIPS will be performed using 6 mm balloon for stent expansion. In the control group, standard TIPS will be performed using progressive balloon dilation, starting at 8 mm and increasing stepwise as needed until the portosystemic pressure gradient is reduced to <12 mm Hg. The primary endpoint is the rebleeding rate over the entire follow-up period after TIPS. Secondary endpoints include the incidence of HE and liver function impairment. All statistical analyses will be performed using SPSS V.27.0 (IBM, Armonk, New York, USA), with a significance level set at p<0.05. Ethics and dissemination: The study protocol (V.2, 1 July 2025) has been approved by the Medical Ethics Committee of the First Affiliated Hospital of Air Force Medical University (Approval No.: KY20252233-F-2). Written informed consent will be obtained from all participants prior to enrolment. Findings will be presented at academic conferences and published in peer-reviewed journals. Trial registration number: ChiCTR2500110490; NCT07253389 .
- 20 November 2025
- Published by Springer Nature in Hepatology International
- Vol. 20 (2) , 428-440
Enhancing post-TIPS hepatic encephalopathy risk stratification: a hybrid TabPFN model leveraging radiomics, deep transfer learning features, and MELD score
Purpose Predicting hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS) is critical for guiding portal hypertension treatment strategies and enabling early intervention. This study aims to employ the Tabular Prior-data Fitted Network (TabPFN) algorithm to develop a machine learning (ML) model that predicts post-TIPS HE. Methods This study retrospectively enrolled 218 patients who underwent TIPS across three hospitals. Preoperative contrast enhanced CT (CECT) scans were used to delineate the volumetric region of interest (VOI) for the liver, spleen, abdominal fat, and abdominal muscle. Radiomics and deep transfer learning (DTL) features were extracted from each VOI. Overt HE occurrence during follow-up was divided into two groups. 171 patients (two hospitals) were randomly split (7:3) into training and validation set, 47 patients (third hospital) formed an external test set. After feature selection, we trained and compared multiple ML models. Shapley additive explanation (SHAP) was performed for model interpretability. Results The overall incidence of overt HE in the study cohort was 20.6%. The combined TabPFN model with the best predictive performance achieved AUCs of 0.953 (training set), 0.870 (validation set), and 0.942 (external test set), with accuracies of 0.933, 0.846, and 0.872, respectively. SHAP analysis identified the liver radiomics signature as a dominant predictors. Time-dependent AUCs at 90, 180, 365, and 730 days exceeded 0.88 in all cohorts, and high-risk patients had significantly higher HE occurrence (p < 0.01). Conclusion A TabPFN-based ML model integrating CECT radiomics, DTL features, and MELD score enables accurate, externally validated prediction of post-TIPS HE, supporting personalized risk stratification and clinical decision-making.
- 20 November 2025
- Published by Springer Nature in Hepatology International
- Vol. 20 (2) , 428-440
Enhancing post-TIPS hepatic encephalopathy risk stratification: a hybrid TabPFN model leveraging radiomics, deep transfer learning features, and MELD score
Purpose Predicting hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS) is critical for guiding portal hypertension treatment strategies and enabling early intervention. This study aims to employ the Tabular Prior-data Fitted Network (TabPFN) algorithm to develop a machine learning (ML) model that predicts post-TIPS HE. Methods This study retrospectively enrolled 218 patients who underwent TIPS across three hospitals. Preoperative contrast enhanced CT (CECT) scans were used to delineate the volumetric region of interest (VOI) for the liver, spleen, abdominal fat, and abdominal muscle. Radiomics and deep transfer learning (DTL) features were extracted from each VOI. Overt HE occurrence during follow-up was divided into two groups. 171 patients (two hospitals) were randomly split (7:3) into training and validation set, 47 patients (third hospital) formed an external test set. After feature selection, we trained and compared multiple ML models. Shapley additive explanation (SHAP) was performed for model interpretability. Results The overall incidence of overt HE in the study cohort was 20.6%. The combined TabPFN model with the best predictive performance achieved AUCs of 0.953 (training set), 0.870 (validation set), and 0.942 (external test set), with accuracies of 0.933, 0.846, and 0.872, respectively. SHAP analysis identified the liver radiomics signature as a dominant predictors. Time-dependent AUCs at 90, 180, 365, and 730 days exceeded 0.88 in all cohorts, and high-risk patients had significantly higher HE occurrence (p < 0.01). Conclusion A TabPFN-based ML model integrating CECT radiomics, DTL features, and MELD score enables accurate, externally validated prediction of post-TIPS HE, supporting personalized risk stratification and clinical decision-making.
- 11 May 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36 (8) , 1330-1335
Transjugular Splenocaval Shunt Creation for the Treatment of Portal Vein Cavernous Transformation with Recurrent Variceal Hemorrhage
- 11 May 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36 (8) , 1330-1335
Transjugular Splenocaval Shunt Creation for the Treatment of Portal Vein Cavernous Transformation with Recurrent Variceal Hemorrhage
- 2 April 2025
- Published by BMJ in Frontline Gastroenterology
- Vol. 16 (5) , 423-425
Refractory gastrointestinal bleeding
We report a rare case of refractory gastrointestinal bleeding due to portal hypertension caused by a gastroduodenal artery-superior mesenteric vein fistula. A 54-year-old woman with a 6-year history of haematemesis and haematochezia was admitted after her most recent bleeding episode. She had endured over 10 episodes of gastrointestinal bleeding, undergone multiple endoscopic procedures and received one percutaneous transhepatic variceal embolisation. One week before admission, she experienced another bleeding episode, necessitating an emergency transjugular intrahepatic portosystemic shunt (TIPS). Six days post-TIPS, she returned with recurrent haematochezia. Preoperative CT revealed significant thickening and dilation of the superior mesenteric vein, indicating a possible fistula, which was confirmed through coeliac trunk angiography. We successfully occluded the fistula, leading to a reduced portal vein pressure gradient and the resolution of her symptoms. Portal hypertension resulting from an arteriovenous fistula is uncommon, and the closure of the fistula is essential for effective treatment.
- 2 April 2025
- Published by BMJ in Frontline Gastroenterology
- Vol. 16 (5) , 423-425
Refractory gastrointestinal bleeding
We report a rare case of refractory gastrointestinal bleeding due to portal hypertension caused by a gastroduodenal artery-superior mesenteric vein fistula. A 54-year-old woman with a 6-year history of haematemesis and haematochezia was admitted after her most recent bleeding episode. She had endured over 10 episodes of gastrointestinal bleeding, undergone multiple endoscopic procedures and received one percutaneous transhepatic variceal embolisation. One week before admission, she experienced another bleeding episode, necessitating an emergency transjugular intrahepatic portosystemic shunt (TIPS). Six days post-TIPS, she returned with recurrent haematochezia. Preoperative CT revealed significant thickening and dilation of the superior mesenteric vein, indicating a possible fistula, which was confirmed through coeliac trunk angiography. We successfully occluded the fistula, leading to a reduced portal vein pressure gradient and the resolution of her symptoms. Portal hypertension resulting from an arteriovenous fistula is uncommon, and the closure of the fistula is essential for effective treatment.
- 26 March 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (6) , 1574-1585
Benefits of TIPS for Patients With Large Ascites Preceding Recurrent or Refractory ascites: A Multicenter Cohort Study
Background and Aim: Patients with recurrent or refractory ascites can benefit from transjugular intrahepatic portosystemic shunt (TIPS). However, the value of TIPS for patients with large ascites remains unclear.Methods: This retrospective multicenter study included patients who underwent TIPS or medicine plus large‐volume paracentesis (medicine + LVP) for ascites between January 2014 and December 2022 at five centers. The primary endpoint was recurrence or worsening of ascites. The secondary endpoints were liver‐related death, all‐cause hemorrhage, overt hepatic encephalopathy (OHE), and shunt dysfunction.Results: Overall, 724 patients were evaluated, including 373 patients with large ascites preceding recurrent or refractory ascites received TIPS (the LA‐TIPS group), 282 patients with recurrent and refractory ascites received TIPS (the RA‐TIPS group), and 69 patients with large ascites preceding recurrent or refractory ascites received medicine + LVP (the LA‐M group). Patients in the LA‐TIPS group had significantly lower incidences of recurrence or worsening of ascites (37.4% vs. 45.3%, p < 0.001), liver‐related death (44.8% vs. 62.0%, p < 0.001), and OHE (47.3% vs. 60.3%, p < 0.001) than those in the RA‐TIPS group. Meanwhile, patients in the LA‐TIPS group had significantly lower incidences of recurrence or worsening of ascites (37.4% vs. 44.6%, p = 0.006) and hemorrhage (38.3% vs. 47.2%, p = 0.042), but a higher incidence of OHE (34.2% vs. 4.5%, p < 0.001) than those in the LA‐M group.Conclusions: In terms of controlling ascites, the benefit of TIPS was greater in patients with large ascites preceding recurrent or refractory ascites, suggesting that TIPS might be considered in patients with large ascites before they progress to recurrent or refractory stages.
- 26 March 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (6) , 1574-1585
Benefits of TIPS for Patients With Large Ascites Preceding Recurrent or Refractory ascites: A Multicenter Cohort Study
Background and Aim: Patients with recurrent or refractory ascites can benefit from transjugular intrahepatic portosystemic shunt (TIPS). However, the value of TIPS for patients with large ascites remains unclear.Methods: This retrospective multicenter study included patients who underwent TIPS or medicine plus large‐volume paracentesis (medicine + LVP) for ascites between January 2014 and December 2022 at five centers. The primary endpoint was recurrence or worsening of ascites. The secondary endpoints were liver‐related death, all‐cause hemorrhage, overt hepatic encephalopathy (OHE), and shunt dysfunction.Results: Overall, 724 patients were evaluated, including 373 patients with large ascites preceding recurrent or refractory ascites received TIPS (the LA‐TIPS group), 282 patients with recurrent and refractory ascites received TIPS (the RA‐TIPS group), and 69 patients with large ascites preceding recurrent or refractory ascites received medicine + LVP (the LA‐M group). Patients in the LA‐TIPS group had significantly lower incidences of recurrence or worsening of ascites (37.4% vs. 45.3%, p < 0.001), liver‐related death (44.8% vs. 62.0%, p < 0.001), and OHE (47.3% vs. 60.3%, p < 0.001) than those in the RA‐TIPS group. Meanwhile, patients in the LA‐TIPS group had significantly lower incidences of recurrence or worsening of ascites (37.4% vs. 44.6%, p = 0.006) and hemorrhage (38.3% vs. 47.2%, p = 0.042), but a higher incidence of OHE (34.2% vs. 4.5%, p < 0.001) than those in the LA‐M group.Conclusions: In terms of controlling ascites, the benefit of TIPS was greater in patients with large ascites preceding recurrent or refractory ascites, suggesting that TIPS might be considered in patients with large ascites before they progress to recurrent or refractory stages.
- 17 February 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (7) , 1183-1196
Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicenter Real‐World Study
Background: Transjugular intrahepatic portosystemic shunt (TIPS) is an established procedure for managing portal hypertension in cirrhotic patients, but the impact of post‐TIPS overt hepatic encephalopathy (OHE) on survival remains controversial. While its effect on short‐term survival is well‐documented, its long‐term implications remain unclear.Aims: This study aims to investigate the long‐term impact of post‐TIPS OHE on mortality in cirrhotic patients for variceal bleeding, focusing on the timing and predictive value of OHE beyond the first year post‐TIPS.Methods: A multicenter, retrospective cohort study was conducted involving 3262 cirrhotic patients who underwent TIPS for variceal bleeding at seven Chinese tertiary centers between January 2010 and June 2020. Clinical data, including demographics, procedure details, post‐TIPS complications and survival outcomes, were collected. The primary endpoints were all‐cause mortality and OHE, with follow‐up until death, liver transplantation or 60 months. Propensity score matching minimised confounding effects, and multivariate Fine‐Grey competing risk models identified independent mortality predictors.Results: During a median follow‐up of 1077 days, 33.2% developed post‐TIPS OHE, associated with higher MELD and Child‐Pugh scores. Among these, 19.3% died, with a median time from OHE onset to death of 947 days. Post‐TIPS OHE was not linked to early survival (within 12 months) but emerged as an independent predictor of long‐term mortality beyond 24 months, consistent across various clinical scenarios.Conclusion: Post‐TIPS OHE does not affect short‐term survival but significantly increases long‐term mortality risk. These findings highlight the need for continuous monitoring and tailored interventions to improve long‐term outcomes in post‐TIPS patients.
- 17 February 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (7) , 1183-1196
Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicenter Real‐World Study
Background: Transjugular intrahepatic portosystemic shunt (TIPS) is an established procedure for managing portal hypertension in cirrhotic patients, but the impact of post‐TIPS overt hepatic encephalopathy (OHE) on survival remains controversial. While its effect on short‐term survival is well‐documented, its long‐term implications remain unclear.Aims: This study aims to investigate the long‐term impact of post‐TIPS OHE on mortality in cirrhotic patients for variceal bleeding, focusing on the timing and predictive value of OHE beyond the first year post‐TIPS.Methods: A multicenter, retrospective cohort study was conducted involving 3262 cirrhotic patients who underwent TIPS for variceal bleeding at seven Chinese tertiary centers between January 2010 and June 2020. Clinical data, including demographics, procedure details, post‐TIPS complications and survival outcomes, were collected. The primary endpoints were all‐cause mortality and OHE, with follow‐up until death, liver transplantation or 60 months. Propensity score matching minimised confounding effects, and multivariate Fine‐Grey competing risk models identified independent mortality predictors.Results: During a median follow‐up of 1077 days, 33.2% developed post‐TIPS OHE, associated with higher MELD and Child‐Pugh scores. Among these, 19.3% died, with a median time from OHE onset to death of 947 days. Post‐TIPS OHE was not linked to early survival (within 12 months) but emerged as an independent predictor of long‐term mortality beyond 24 months, consistent across various clinical scenarios.Conclusion: Post‐TIPS OHE does not affect short‐term survival but significantly increases long‐term mortality risk. These findings highlight the need for continuous monitoring and tailored interventions to improve long‐term outcomes in post‐TIPS patients.
- 30 August 2024
- Published by Springer Nature in European Radiology
- Vol. 35 (6) , 3256-3261
Transjugular mesenteric-caval shunt for portal vein cavernous transformation with recurrent variceal bleeding: preliminary results
Objectives This study aimed to evaluate the feasibility, safety, and efficacy of the transjugular mesenteric-caval shunt (TMCS) as a treatment for the cavernous transformation of the portal vein (CTPV) and recurrent variceal bleeding. Methods This retrospective case series was conducted with approval from the institutional review board. It involved seven patients diagnosed with CTPV and recurrent variceal bleeding who underwent the TMCS procedure. We analyzed the rate of procedural complications, incidents of rebleeding, stent stenosis, hepatic encephalopathy, and overall survival to assess treatment outcomes. Results The TMCS was successfully performed in all seven patients without any life-threatening complications. Postoperatively, one patient developed a lung infection and pleural effusion, which resolved with appropriate treatment. Additionally, two patients experienced an increase in total bilirubin levels, but there was no further deterioration in liver function. The median portal pressure gradient significantly decreased from a preoperative value of 27 mmHg (range 20–36 mmHg) to a postoperative value of 6 mmHg (range 4–11 mmHg). A notable improvement was observed in one cirrhotic patient, with liver function progressing from Child-Pugh class B (score 9) to class A (score 6). Over a median follow-up period of 14 months (range 7–18 months), none of the patients encountered rebleeding, stent stenosis, hepatic encephalopathy, or mortality. Conclusion The TMCS appears to be a viable and effective alternative for managing CTPV with recurrent variceal bleeding. Its long-term outcome requires further evaluation. Clinical relevance statement TMCS provides a promising treatment for patients with life-threatening CTPV complications when occluded portal vein cannot be recanalized and portal vein recanalization TIPS is not an option. Key Points Performing TIPS in patients with portal vein cavernoma is complex due to the requirement for recanalization of the occluded portal vein. Creating a mesenteric-caval shunt through a transjugular approach is a feasible technique. Establishing a TMCS provides a means to manage life-threatening complications arising from portal vein cavernoma.
- 30 August 2024
- Published by Springer Nature in European Radiology
- Vol. 35 (6) , 3256-3261
Transjugular mesenteric-caval shunt for portal vein cavernous transformation with recurrent variceal bleeding: preliminary results
Objectives This study aimed to evaluate the feasibility, safety, and efficacy of the transjugular mesenteric-caval shunt (TMCS) as a treatment for the cavernous transformation of the portal vein (CTPV) and recurrent variceal bleeding. Methods This retrospective case series was conducted with approval from the institutional review board. It involved seven patients diagnosed with CTPV and recurrent variceal bleeding who underwent the TMCS procedure. We analyzed the rate of procedural complications, incidents of rebleeding, stent stenosis, hepatic encephalopathy, and overall survival to assess treatment outcomes. Results The TMCS was successfully performed in all seven patients without any life-threatening complications. Postoperatively, one patient developed a lung infection and pleural effusion, which resolved with appropriate treatment. Additionally, two patients experienced an increase in total bilirubin levels, but there was no further deterioration in liver function. The median portal pressure gradient significantly decreased from a preoperative value of 27 mmHg (range 20–36 mmHg) to a postoperative value of 6 mmHg (range 4–11 mmHg). A notable improvement was observed in one cirrhotic patient, with liver function progressing from Child-Pugh class B (score 9) to class A (score 6). Over a median follow-up period of 14 months (range 7–18 months), none of the patients encountered rebleeding, stent stenosis, hepatic encephalopathy, or mortality. Conclusion The TMCS appears to be a viable and effective alternative for managing CTPV with recurrent variceal bleeding. Its long-term outcome requires further evaluation. Clinical relevance statement TMCS provides a promising treatment for patients with life-threatening CTPV complications when occluded portal vein cannot be recanalized and portal vein recanalization TIPS is not an option. Key Points Performing TIPS in patients with portal vein cavernoma is complex due to the requirement for recanalization of the occluded portal vein. Creating a mesenteric-caval shunt through a transjugular approach is a feasible technique. Establishing a TMCS provides a means to manage life-threatening complications arising from portal vein cavernoma.
- Open Access
- 15 July 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1401900
Efficacy and safety of variceal embolization for primary prophylaxis in cirrhosis patients with challenges in standard treatments: preliminary results
Objectives: Nonselective beta blockers (NSBBs) or endoscopic therapies are currently recommended by guidelines for preventing the first variceal bleed in patients with high-risk varices. However, there is a lack of detailed treatment strategies for patients who are intolerant to both NSBBs and endoscopic approaches. Our study aimed to assess the efficacy and safety of variceal embolization as a primary prophylaxis method in cirrhosis patients who are not suitable candidates for NSBBs or endoscopic treatments.Methods: The study included 43 cirrhotic patients with high-risk varices who were candidates for primary prophylaxis against variceal bleeding. These patients underwent variceal embolization at the Xijing Hospital between January 2020 and June 2022. The primary endpoint was the occurrence of bleeding from varices, and the secondary endpoints were the recurrence of varices and the emergence of complications.Results: The procedure of variceal embolization had a success rate of 93.0% (40 out of 43 patients). Over a 2-year follow-up period, the rate of variceal bleeding was 11.6% (5 out of 43 patients), the recurrence rate of varices was 14.0% (6 out of 43 patients), and the rate of severe complications was limited to 2.3% (1 out of 43 patients).Conclusion: Variceal embolization is a viable primary prophylactic intervention for cirrhotic patients who are at risk of variceal bleeding when standard treatments, such as NSBBs or endoscopic therapies, are difficult to perform.
- 15 July 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1401900
Open AccessEfficacy and safety of variceal embolization for primary prophylaxis in cirrhosis patients with challenges in standard treatments: preliminary results
Objectives: Nonselective beta blockers (NSBBs) or endoscopic therapies are currently recommended by guidelines for preventing the first variceal bleed in patients with high-risk varices. However, there is a lack of detailed treatment strategies for patients who are intolerant to both NSBBs and endoscopic approaches. Our study aimed to assess the efficacy and safety of variceal embolization as a primary prophylaxis method in cirrhosis patients who are not suitable candidates for NSBBs or endoscopic treatments.Methods: The study included 43 cirrhotic patients with high-risk varices who were candidates for primary prophylaxis against variceal bleeding. These patients underwent variceal embolization at the Xijing Hospital between January 2020 and June 2022. The primary endpoint was the occurrence of bleeding from varices, and the secondary endpoints were the recurrence of varices and the emergence of complications.Results: The procedure of variceal embolization had a success rate of 93.0% (40 out of 43 patients). Over a 2-year follow-up period, the rate of variceal bleeding was 11.6% (5 out of 43 patients), the recurrence rate of varices was 14.0% (6 out of 43 patients), and the rate of severe complications was limited to 2.3% (1 out of 43 patients).Conclusion: Variceal embolization is a viable primary prophylactic intervention for cirrhotic patients who are at risk of variceal bleeding when standard treatments, such as NSBBs or endoscopic therapies, are difficult to perform.
- Open Access
- 25 April 2023
- Published by Springer Nature in Hepatology International
- Vol. 17 (4) , 979-988
Transjugular intrahepatic collateral-systemic shunt is effective for cavernous transformation of the portal vein with variceal bleeding
Background: The transjugular intrahepatic portal collateral-systemic shunt (transcollateral TIPS) is used to treat portal hypertension-related complications in patients with cavernous transformation of the portal vein (CTPV) and whose main portal vein cannot be recanalized. It is still not clear whether transcollateral TIPS can be as effective as portal vein recanalization–transjugular intrahepatic portosystemic shunt (PVR–TIPS). This study aimed to evaluate the efficacy and safety of transcollateral TIPS in the treatment of refractory variceal bleeding with CTPV. Methods: Patients with refractory variceal bleeding caused by CTPV were selected from the database of consecutive patients treated with TIPS in Xijing Hospital from January 2015 to March 2022. They were divided into the transcollateral TIPS group and the PVR–TIPS group. The rebleeding rate, overall survival, shunt dysfunction, overt hepatic encephalopathy (OHE) and operation-related complications were analyzed. Results: A total of 192 patients were enrolled, including 21 patients with transcollateral TIPS and 171 patients with PVR–TIPS. Compared with the patients with PVR–TIPS, the patients with transcollateral TIPS had more noncirrhosis (52.4 vs. 19.9%, p = 0.002), underwent fewer splenectomies (14.3 vs. 40.9%, p = 0.018), and had more extensive thromboses (38.1 vs. 15.2%, p = 0.026). There were no differences in rebleeding, survival, shunt dysfunction, or operation-related complication rates between the transcollateral TIPS and PVR–TIPS groups. However, the OHE rate was significantly lower in the transcollateral TIPS group (9.5 vs. 35.1%, p = 0.018). Conclusion: Transcollateral TIPS is an effective treatment for CTPV with refractory variceal bleeding.
- 25 April 2023
- Published by Springer Nature in Hepatology International
- Vol. 17 (4) , 979-988
Open AccessTransjugular intrahepatic collateral-systemic shunt is effective for cavernous transformation of the portal vein with variceal bleeding
Background: The transjugular intrahepatic portal collateral-systemic shunt (transcollateral TIPS) is used to treat portal hypertension-related complications in patients with cavernous transformation of the portal vein (CTPV) and whose main portal vein cannot be recanalized. It is still not clear whether transcollateral TIPS can be as effective as portal vein recanalization–transjugular intrahepatic portosystemic shunt (PVR–TIPS). This study aimed to evaluate the efficacy and safety of transcollateral TIPS in the treatment of refractory variceal bleeding with CTPV. Methods: Patients with refractory variceal bleeding caused by CTPV were selected from the database of consecutive patients treated with TIPS in Xijing Hospital from January 2015 to March 2022. They were divided into the transcollateral TIPS group and the PVR–TIPS group. The rebleeding rate, overall survival, shunt dysfunction, overt hepatic encephalopathy (OHE) and operation-related complications were analyzed. Results: A total of 192 patients were enrolled, including 21 patients with transcollateral TIPS and 171 patients with PVR–TIPS. Compared with the patients with PVR–TIPS, the patients with transcollateral TIPS had more noncirrhosis (52.4 vs. 19.9%, p = 0.002), underwent fewer splenectomies (14.3 vs. 40.9%, p = 0.018), and had more extensive thromboses (38.1 vs. 15.2%, p = 0.026). There were no differences in rebleeding, survival, shunt dysfunction, or operation-related complication rates between the transcollateral TIPS and PVR–TIPS groups. However, the OHE rate was significantly lower in the transcollateral TIPS group (9.5 vs. 35.1%, p = 0.018). Conclusion: Transcollateral TIPS is an effective treatment for CTPV with refractory variceal bleeding.